Navigation Links
Mylan to Acquire Pfizer Respiratory Delivery Platform
Date:11/9/2011

PITTSBURGH, Nov. 9, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into an agreement with Pfizer for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to GlaxoSmithKline's Advair® Diskus and Seretide® Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform. Advair® Diskus and Seretide® Diskus are inhaled fixed-dose combinations of Fluticasone Propionate and Salmeterol delivered via a dry powder inhaler and are used to treat asthma and COPD (chronic obstructive pulmonary disorder).

In addition, Pfizer will grant Mylan rights to its dry-powder delivery platform to develop and commercialize additional brand and generic pharmaceutical products, including rights of negotiation for certain existing Pfizer compounds currently in various stages of development.

In connection with the transaction, Mylan will employ select key members of the former Pfizer respiratory inhalation development team based at Discovery Park in Sandwich, U.K., where Mylan will establish a respiratory development division. Some employees also will be based in Cambridge, U.K.

Mylan Chairman and CEO Robert J. Coury said: "Mylan's acquisition of rights to Pfizer's inhalation technology platform delivers on yet another one of our key strategic objectives by filling an important gap in our product portfolio and builds a truly world-class respiratory franchise for Mylan. I would like to personally welcome to Mylan the talented former Pfizer employees who will be joining us. This team's core competency in respiratory brings Mylan deep knowledge and expertise that will allow us to fully leverage this exciting delivery platform. We will be establishing a 'center of excellence' in respiratory at Discovery Park in Sandwich and believe this franchise will serve as an additional co
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
2. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
3. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
4. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
5. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
6. Mylan Receives Approval for Generic Version of GoLytely(R)
7. Mylan Declares Quarterly Preferred Stock Dividend
8. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
9. Mylan Confirms First-to-File Patent Challenge Relating to Vytorin(R) Cholesterol Medication
10. Mylans President of Europe, Middle East and Africa Elected President of European Generic Medicines Association
11. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... -- UBM Medica US today announced the launch of ... information resource for neurologists and other healthcare providers to ... neurological disorders . The prevalence of ... access to dedicated information for healthcare providers who treat ... , 1 in 6 people are affected ...
(Date:7/23/2014)... , July 23, 2014 Research ... "Diagnostic Electrocardiograph (ECG) Market by Product, End-user & by ... to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is segmented into three major segments, namely, holter monitor, ... market was valued at $3,683 million in 2013 and ...
(Date:7/23/2014)... 23, 2014 /PRNewswire-iReach/ -- The Centers for Medicare & ... Innovation Network-Quality Improvement Organization (QIN-QIO) contract to a partnership ... Effective August 1, WVMI will launch Quality Insights ... , Pennsylvania , Delaware ... Louisiana.  The Network will engage providers and the community ...
Breaking Medicine Technology:UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 2Global Diagnostic Electrocardiograph (Resting, Stress, Holter Monitor) (ECG) Market - Forecast to 2020 3Announcing a New Regional Approach to Medicare Quality Improvement 2
... 20, 2012   Sysmex America, Inc., a global leader ... today announced its 200th placement of Sysmex WAM ... Laboratory.  Sysmex WAM is now connecting nearly 600 sites ... U.S. and Canada. Sysmex WAM plays a key role ...
... Assured Pharmacy (Pinksheets: APHY), a leading specialty pharmacy group ... present at Anda,s 2012 Supply Chain Symposium on Thursday, ... in Palm Beach Gardens, Florida.  Assured Pharmacy has been ... dispensing controlled substances at pharmacies.   Anda ...
Cached Medicine Technology:Sysmex America Achieves Clinical Laboratory Connectivity Milestone 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 2Assured Pharmacy to Present at Anda's 2012 Supply Chain Symposium 3
(Date:7/23/2014)... July 24, 2014 The routine ... UPMC greatly increases the likelihood of performing the ... and cancer, report researchers from the University of ... , The test, available at the UPMC/UPCI Multidisciplinary ... the chances of patients getting the correct initial ...
(Date:7/23/2014)... 23, 2014 Men and women who ... for life insurance based on national averages. The Quotes ... rates search to its comprehensive tool this year to ... . , Providers that are now underwriting plans ... reviewed in one or two clicks. The intelligent platform ...
(Date:7/23/2014)... Sellafield or Dounreay since the 1990s are not at ... published in the British Journal of Cancer ... Group at the University of Oxford and from Newcastle ... those who were under 25 and living near Sellafield ... cancer incidence from 1991-2006 between those living near these ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 A new ... a power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally ... cancers throughout a woman’s body, Bernstein Liebhard LLP reports. ... the Journal of the American Medical Association, looked at ... morcellator at 500 U.S. hospitals from 2006 to 2012. ...
(Date:7/23/2014)... PA) Asking patients if a suspicious skin lesion ... the spot is likely to be cancerous, according to ... of the Department of Dermatology at Temple University School ... JAMA Dermatology on July 23, 2014, found that ... accompanied by itching, while 28.2 percent involve pain. Non-melanoma ...
Breaking Medicine News(10 mins):Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 2Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 3Health News:UPMC-Developed Test Increases Odds of Correct Surgery for Thyroid Cancer Patients 4Health News:Cheap Life Insurance Rates for Married Couples Added to Search System at Insurer Portal Online 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Research led by Temple's chair of dermatology: Pain and itch may be signs of skin cancer 2
... A new type of diagnostic imaging - which can ... cancerous - could be used to prevent unnecessary surgery ... A study by Belgian researchers, which will be ... Society,s Annual Congress in Amsterdam, found that the new ...
... in moderate quantities can reduce the risk of asthma, according ... today (25 September 2011) at the European Respiratory Society,s Annual ... a week could reduce the risk of developing the condition. ... of 12 and 41 yrs of age. All participants completed ...
... A major UK trial has produced firm evidence that ... with early breast cancer significantly reduces the risk of ... The treatment, known as synchronous chemoradiation, has minimal adverse ... of life. Findings from the SEquencing of ...
... of the care of patients with rectal cancer have ... chemotherapy and radiotherapy between European countries. The European ... the European CanCer Organisation compared the treatment ... Netherlands who were diagnosed with rectal cancer between 2008 ...
... for patients with bone metastases from advanced prostate cancer ... III study of an alpha-pharmaceutical in these patients has ... research reported today (Saturday) at the 2011 European Multidisciplinary ... Parker, Consultant Clinical Oncologist at the Royal Marsden Hospital, ...
... Sept. 23 (HealthDay News) -- People,s bodies build up vitamin ... black men who live in areas of the United States ... deficiency than whites who live in the same places. ... recommendations need to change. "This study shows that across-the-board vitamin ...
Cached Medicine News:Health News:New diagnostic imaging for lung cancer could prevent unnecessary surgery 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 3Health News:Treatment of rectal cancer varies enormously between different European countries 2Health News:Treatment of rectal cancer varies enormously between different European countries 3Health News:First Phase III trial of an alpha-pharmaceutical 2Health News:First Phase III trial of an alpha-pharmaceutical 3Health News:Many Black Men in Cold Climates Lack Vitamin D 2
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
The Claiborne brand provides the perfect look for the man who wants to be comfortable and relaxed, yet look appropriate for each occasion....
The Liz Claiborne eyewear collection features feminine, classic, progressive friendly designs that meet the needs of today's women. The high quality frames are modern, but not trendy....
Medicine Products: